Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab open-label phase 2 study in pediatric generalized myasthenia gravis
2021-002479-20Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nipocalimab in myasthenia gravis (MG), sponsored by Janssen Pharmaceutical. Started Apr 2022; status: active.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2021-002479-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002479-20.